These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 19837455)

  • 21. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
    Bourrier A; Carrat F; Colombel JF; Bouvier AM; Abitbol V; Marteau P; Cosnes J; Simon T; Peyrin-Biroulet L; Beaugerie L;
    Aliment Pharmacol Ther; 2016 Jan; 43(2):252-61. PubMed ID: 26549003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
    Chaparro M; Ordás I; Cabré E; Garcia-Sanchez V; Bastida G; Peñalva M; Gomollón F; García-Planella E; Merino O; Gutiérrez A; Esteve M; Márquez L; Garcia-Sepulcre M; Hinojosa J; Vera I; Muñoz F; Mendoza JL; Cabriada JL; Montoro MA; Barreiro-de Acosta M; Ceña G; Saro C; Aldeguer X; Barrio J; Maté J; Gisbert JP
    Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Better survival of renal cell carcinoma in patients with inflammatory bowel disease.
    Derikx LA; Nissen LH; Drenth JP; van Herpen CM; Kievit W; Verhoeven RH; Mulders PF; Hulsbergen-van de Kaa CA; Boers-Sonderen MJ; van den Heuvel TR; Pierik M; Nagtegaal ID; Hoentjen F; ; ;
    Oncotarget; 2015 Nov; 6(35):38336-47. PubMed ID: 26447542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
    Müller KE; Lakatos PL; Arató A; Kovács JB; Várkonyi Á; Szűcs D; Szakos E; Sólyom E; Kovács M; Polgár M; Nemes É; Guthy I; Tokodi I; Tóth G; Horváth Á; Tárnok A; Csoszánszki N; Balogh M; Vass N; Bódi P; Dezsőfi A; Gárdos L; Micskey E; Papp M; Cseh Á; Szabó D; Vörös P; Veres G;
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):576-82. PubMed ID: 23820399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
    Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
    Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.
    Rungoe C; Langholz E; Andersson M; Basit S; Nielsen NM; Wohlfahrt J; Jess T
    Gut; 2014 Oct; 63(10):1607-16. PubMed ID: 24056767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paediatric inflammatory bowel disease in New Zealand.
    Yap J; Wesley A; Mouat S; Chin S
    N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
    Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
    J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
    Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
    Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey.
    Saibeni S; Kohn A; Meucci G; Papi C;
    Dig Liver Dis; 2015 Feb; 47(2):170-3. PubMed ID: 25467827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hodgkin's lymphoma associated with inflammatory bowel disease treated with thiopurines. A case report and review of the literature].
    Maira González N; Scocco S; Estepa R
    Rev Esp Patol; 2019; 52(4):242-245. PubMed ID: 31530407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
    Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.
    Sokol H; Beaugerie L
    Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
    Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
    Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists.
    Duchesne C; Faure P; Kohler F; Pingannaud MP; Bonnaud G; Devulder F; Abramowitz L; Boustière C; Peyrin-Biroulet L;
    Dig Liver Dis; 2014 Aug; 46(8):675-81. PubMed ID: 24809234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.